Cargando…

Convalescent plasma for COVID-19: the risk of pulmonary embolism should not be underestimated!

Detalles Bibliográficos
Autores principales:	Sanfilippo, F., La Rosa, V., Oliveri, F., Astuto, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7453861/ https://www.ncbi.nlm.nih.gov/pubmed/32859242 http://dx.doi.org/10.1186/s13054-020-03236-3

Ejemplares similares

COVID-19, Hypercoagulability, and Cautiousness with Convalescent Plasma
por: Sanfilippo, Filippo, et al.
Publicado: (2021)

Micro-Thrombosis, Perfusion Defects, and Worsening Oxygenation in COVID-19 Patients: A Word of Caution on the Use of Convalescent Plasma
por: Sanfilippo, Filippo, et al.
Publicado: (2021)

Convalescent plasma for covid19 – How long should a donor be excluded from donation?
por: Kutner, Jose M., et al.
Publicado: (2020)

Convalescent plasma for patients with COVID-19
por: Zeng, Furong, et al.
Publicado: (2020)

Current studies of convalescent plasma therapy for COVID-19 may underestimate risk of antibody-dependent enhancement
por: Fleming, Andrew B., et al.
Publicado: (2020)

Convalescent plasma for COVID-19 considerations
por: Adiwinata Pawitan, Jeanne
Publicado: (2021)

Why should we use convalescent plasma for COVID-19?
por: Franchini, Massimo
Publicado: (2020)

Successful spontaneous breathing trial, early reintubation and mechanisms of weaning failure
por: Sanfilippo, Filippo, et al.
Publicado: (2020)

Convalescent plasma in the management of COVID-19 pneumonia
por: Elbadawi, Ayman, et al.
Publicado: (2021)

How Safe Is COVID-19 Convalescent Plasma?
por: Franchini, Massimo, et al.
Publicado: (2021)

COVID-19 convalescent plasma therapy and immunodeficiency
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

The importance of a “socially responsible” approach during COVID-19: the invisible heroes of science in Italy
por: Sanfilippo, Filippo, et al.
Publicado: (2020)

Risk–benefit analysis on the clinical significance of convalescent plasma therapy in the management of COVID-19
por: Dhanasekaran, Sivaraman, et al.
Publicado: (2020)

‘Treatment of COVID-19 with convalescent plasma’ – Author’s reply
por: Wooding, Denise J., et al.
Publicado: (2021)

Use of convalescent plasma in COVID-19 patients in China
por: Zhu, M., et al.
Publicado: (2020)

Convalescent plasma (CP) therapy in patients with COVID-19
por: Cakir, Banu
Publicado: (2021)

In Reply—How Safe Is COVID-19 Convalescent Plasma?
por: Joyner, Michael J., et al.
Publicado: (2021)

High-risk Pulmonary Embolism: Should We Be Less Patient with Thrombolytic Therapy?
por: Yıldırım, Fatma, et al.
Publicado: (2017)

How should we use convalescent plasma therapies for the management of COVID-19?
por: Wood, Erica M., et al.
Publicado: (2021)

Get rid of the bad first: Therapeutic plasma exchange with convalescent plasma for severe COVID-19
por: Kesici, Selman, et al.
Publicado: (2020)

COVID-19 convalescent plasma therapy for immunodeficient patients–weighing up risks and benefits
por: Vuk, T., et al.
Publicado: (2021)

High-Dose Convalescent Plasma for Treatment of Severe COVID-19
por: Focosi, Daniele, et al.
Publicado: (2022)

Covid-19 convalescent plasma and SARS-CoV-2 viral variants
por: Joob, B., et al.
Publicado: (2021)

Fatal VAP-related pulmonary aspergillosis by Aspergillus niger in a positive COVID-19 patient
por: Trovato, Laura, et al.
Publicado: (2021)

The strong rationale for the use of dexmedetomidine instead of fentanyl as adjuvant to ropivacaine for epidural anaesthesia
por: Sanfilippo, Filippo, et al.
Publicado: (2021)

Limitations of Safety Update on Convalescent Plasma Transfusion in COVID-19 Patients
por: Farag, Youssef M.K.
Publicado: (2020)

Convalescent plasma to treat COVID-19: Its challenges in Iraq's situation
por: Hashim, H.T.
Publicado: (2020)

Use of convalescent plasma in hospitalized patients with COVID-19: case series
por: Hegerova, Livia, et al.
Publicado: (2020)

Challenges in the production of COVID-19 convalescent plasma- analysis of donor recruitment
por: Sekiya, Eliseo Joji, et al.
Publicado: (2021)

High-Dose Convalescent Plasma for Treatment of Severe COVID-19 (response)
por: De Santis, Gil C., et al.
Publicado: (2022)

COVID-19 vaccination: The impact on the selection criteria of the convalescent plasma donors
por: Bansal, N., et al.
Publicado: (2021)

Vaccine-boosted convalescent plasma therapy for patients with immunosuppression and COVID-19
por: Ripoll, Juan G., et al.
Publicado: (2022)

The emergency use authorization for COVID‐19 convalescent plasma reduced mortality
por: Paneth, Nigel, et al.
Publicado: (2023)

Convalescent plasma: A possible treatment of COVID-19 in India
por: Teixeira da Silva, Jaime A.
Publicado: (2020)

Surgical pulmonary embolectomy – an underestimated treatment option
por: Zieliński, Dariusz, et al.
Publicado: (2022)

COVID-19 convalescent plasma
por: Tobian, Aaron A. R., et al.
Publicado: (2022)

Convalescent Plasma in COVID-19: To what Degree should Clinicians Rely on Currently Available Data?
por: Alhazzani, Waleed, et al.
Publicado: (2021)

Early Convalescent Plasma for High-Risk Outpatients with Covid-19
por: Korley, Frederick K., et al.
Publicado: (2021)

In Reply — Limitations of Safety Update on Convalescent Plasma Transfusion in COVID-19 Patients
por: Joyner, Michael. J., et al.
Publicado: (2020)

Early and persistent viral clearance in COVID-19 patients treated with convalescent plasma
por: Franchini, Massimo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_skkkh6bomp1kom2uqusg3grnfq